Shenzhen Tiandaxing Gene Engineering

Shenzhen Tiandaxing Gene Engineering is a Chinese biotechnology company specializing in the development and manufacture of recombinant protein drugs. Founded in 1993 and based in Shenzhen, the company is best known for its flagship product, Anfulong (recombinant human interferon alpha-2b), which is used to treat viral hepatitis and various cancers. It also produces recombinant human granulocyte colony-stimulating factor (G-CSF) for the treatment of neutropenia. The company operates as a subsidiary of Harbin Pharmaceutical Group (Hayao), leveraging its GMP-certified facilities to supply the domestic Chinese market. As a pioneer in China's biopharmaceutical sector, it focuses on the industrialization of genetic engineering technologies and maintains large-scale fermentation and purification capabilities.